Resmed INC 8-K filings

ResMed Inc. announced robust fourth quarter and full fiscal year 2026 results, highlighted by record revenue, increased earnings per share, and a 10% hike in its quarterly dividend.

ResMed Inc. announced an agreement to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in an all-cash transaction, aiming to sharpen its focus on sleep and connected care markets.

ResMed reported strong third-quarter fiscal 2026 results with 11% revenue growth and significant margin expansion.

ResMed Inc. announced robust second-quarter fiscal year 2026 results, with revenue up 11% and non-GAAP diluted EPS increasing by 16%, alongside a declared quarterly cash dividend of $0.60 per share.

ResMed Inc. announced board changes and stockholder approval of amendments to its 2009 Incentive Award Plan and 2018 Employee Stock Purchase Plan, increasing share reserves for employee compensation.

ResMed Inc. reports a strong start to fiscal year 2026 with a 9% revenue increase and significant gross margin expansion, alongside a declared quarterly dividend.

ResMed Inc. announced the election of Nicole Mowad-Nassar to its board of directors and the upcoming retirement of long-serving board member Richard Sulpizio.

ResMed Inc. announced the resignation of Bobby Ghoshal, Chief Commercial Officer of its Residential Care Software business, effective August 1, 2025.

ResMed Inc. announced robust financial performance for the fourth quarter and full fiscal year 2025, marked by significant revenue and profit growth and an increased quarterly cash dividend.

ResMed reports an 8% increase in revenue and a 14% rise in operating profit for the third quarter of fiscal year 2025, driven by strong demand for its sleep devices and software solutions.

ResMed Inc. announced a 10% year-over-year revenue increase and a 52% jump in operating profit for the second quarter of fiscal year 2025, highlighting strong demand for its sleep and breathing health products.

ResMed Inc. held its annual stockholders meeting on November 20, 2024, where eleven directors were elected, KPMG LLP was ratified as the independent auditor, and executive compensation was approved on an advisory basis.

ResMed announced an 11% year-over-year revenue increase and a 34% rise in operating profit for the first quarter of fiscal year 2025.

ResMed has expanded its board of directors by appointing Christopher DelOrefice, the current CFO of Becton Dickinson, effective immediately.

ResMed Inc. announced a 9% year-over-year revenue increase for the fourth quarter of fiscal year 2024, alongside a 38% rise in operating profit, highlighting strong performance across all business sectors.

ResMed's third quarter fiscal year 2024 results show a 7% year-over-year revenue increase and a 25% rise in operating profit, fueled by strong demand for their products and software.

ResMed's second quarter fiscal year 2024 saw a 12% revenue increase and a 20% rise in non-GAAP operating profit, fueled by strong growth across its device, mask, and software businesses.